^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | SynKIR-110 (Mesothelin-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110
Published date:
04/05/2023
Excerpt:
Verismo Therapeutics...today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110, for the treatment of patients with mesothelioma.
